Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Saved in:
| Title: | Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. |
|---|---|
| Authors: | Gligorov, J.1 joseph.gligorov@aphp.fr, Ataseven, B.2, Verrill, M.3, De Laurentiis, M.4, Jung, K.H.5, Azim, H.A.6, Al-Sakaff, N.7, Lauer, S.8, Shing, M.9, Pivot, X.10 |
| Source: | European Journal of Cancer. Sep2017, Vol. 82, p237-246. 10p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 124419923 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Gligorov%2C+J%2E%22">Gligorov, J.</searchLink><relatesTo>1</relatesTo><i> joseph.gligorov@aphp.fr</i><br /><searchLink fieldCode="AR" term="%22Ataseven%2C+B%2E%22">Ataseven, B.</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Verrill%2C+M%2E%22">Verrill, M.</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22De+Laurentiis%2C+M%2E%22">De Laurentiis, M.</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Jung%2C+K%2EH%2E%22">Jung, K.H.</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Azim%2C+H%2EA%2E%22">Azim, H.A.</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22Al-Sakaff%2C+N%2E%22">Al-Sakaff, N.</searchLink><relatesTo>7</relatesTo><br /><searchLink fieldCode="AR" term="%22Lauer%2C+S%2E%22">Lauer, S.</searchLink><relatesTo>8</relatesTo><br /><searchLink fieldCode="AR" term="%22Shing%2C+M%2E%22">Shing, M.</searchLink><relatesTo>9</relatesTo><br /><searchLink fieldCode="AR" term="%22Pivot%2C+X%2E%22">Pivot, X.</searchLink><relatesTo>10</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22European+Journal+of+Cancer%22">European Journal of Cancer</searchLink>. Sep2017, Vol. 82, p237-246. 10p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=124419923 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.ejca.2017.05.010 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 10 StartPage: 237 Titles: – TitleFull: Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Gligorov, J. – PersonEntity: Name: NameFull: Ataseven, B. – PersonEntity: Name: NameFull: Verrill, M. – PersonEntity: Name: NameFull: De Laurentiis, M. – PersonEntity: Name: NameFull: Jung, K.H. – PersonEntity: Name: NameFull: Azim, H.A. – PersonEntity: Name: NameFull: Al-Sakaff, N. – PersonEntity: Name: NameFull: Lauer, S. – PersonEntity: Name: NameFull: Shing, M. – PersonEntity: Name: NameFull: Pivot, X. IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 09 Text: Sep2017 Type: published Y: 2017 Identifiers: – Type: issn-print Value: 09598049 Numbering: – Type: volume Value: 82 Titles: – TitleFull: European Journal of Cancer Type: main |
| ResultId | 1 |
